Cocrystal Pharma Reports 2026 Annual Meeting Vote Results

What Happened

• Cocrystal Pharma, Inc. filed an 8-K on July 17, 2026 reporting the results of its 2026 Annual Meeting held July 14, 2026. Stockholders elected five directors and ratified Weinberg & Company as the company’s independent registered public accounting firm for fiscal 2026. Because the director elections and auditor ratification received sufficient votes, a proposed adjournment (Proposal 3) was rendered moot.

Key Details

• Director election vote totals (For / Abstentions / Broker non-votes):
  • Dr. Roger Kornberg: 6,113,868 / 392,124 / 2,860,552
  • Dr. Phillip Frost: 6,276,012 / 229,980 / 2,860,552
  • Mr. Fred Hassan: 6,293,331 / 212,661 / 2,860,552
  • Mr. Richard C. Pfenniger, Jr.: 5,964,606 / 541,386 / 2,860,552
  • Mr. Steven Rubin: 5,914,522 / 591,470 / 2,860,552
• Auditor ratification (Proposal 2): Votes for 9,181,034; against 174,923; abstentions 10,587.
• The same 2,860,552 broker non-votes were recorded for each director election.

Why It Matters

• The results confirm the company’s board lineup and governance continuity through the next annual meeting, which is relevant for shareholders monitoring management oversight and strategic direction. Ratification of Weinberg & Company as the independent auditor finalizes the firm responsible for auditing Cocrystal’s FY2026 financial statements. The presence of substantial broker non-votes in the director elections indicates a portion of shares held by brokers without voting instructions, which can affect outcomes for certain proposals but did not prevent approval here.